Skip to content
Peptide research

Thymalin

Also known as Thymaline
Category
Immune & Defense
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

A thymic peptide extract marketed to restore immune function and normalize T-cell balance in aging adults. Evidence is low confidence throughout: claims of reduced mortality, extended lifespan, and better severe COVID-19 outcomes rest on small, older, or animal studies, not robust human trials. Western safety data is limited and most supply is unregulated research-grade product of uncertain purity. Not an approved drug in the US.

Read Full record

Studied uses & evidence

Studied uses(6)

  • Reduction of all-cause mortality in elderly patients via immune restoration

    Low

    Based on one unblinded, non-randomized human cohort study, never independently replicated.

  • Stimulation of hematopoietic stem cell differentiation into mature T-lymphocytes

    Low

    Demonstrated in one human cell-culture study only, with no in vivo confirmation yet.

  • Extended lifespan and reduced spontaneous carcinogenesis in animal models

    Low

    Consistent rodent data from one research group, with modest effects on average lifespan.

Evidence limits

Evidence Level
Moderate

Thymalin has a more substantial clinical evidence base than most Khavinson bioregulators, owing to its pharmaceutical status in Russia since 1982 and the 40+ years of clinical application. The strongest evidence comes from the 266-patient elderly longevity study demonstrating 2.0-2.1-fold mortality reduction over 6-8 years (and 4.1-fold with combined annual treatment), and the COVID-19 study showing halved hospital mortality in severe elderly patients receiving Thymalin as adjunctive therapy. The listed rat and CBA-mouse lifespan studies tested synthetic peptides rather than Thymalin extract. The Glu-Trp rat study found similar mean lifespan, although the longest-lived animals survived longer and tumor incidence decreased. Mechanistic evidence is well-characterized: Thymalin stimulates hematopoietic stem cell differentiation into mature T-lymphocytes (6.8-fold CD28 increase), activates T-cell immunity, and regulates gene expression through direct DNA binding. Major limitations: the human longevity study was not an RCT, all research originates from Khavinson-affiliated groups, no independent Western replication exists, and no FDA-standard clinical trials have been conducted.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Organ transplant recipients

    High

    Thymic peptide immune stimulation may counteract immunosuppressive therapy.

  • Active autoimmune disease

    Moderate

    Immune modulation via thymic peptides may exacerbate autoimmune conditions.

General cautions

  • Pregnancy

    Absolute

    No reproductive safety data.

Risk summary(7)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Potential interference with immunosuppressive therapy

    Theoretical
  • Limited Western safety data and lack of independent validation

    High
  • Theoretical risk of immune overstimulation or autoimmunity

    Theoretical
  • Caution with active thymic tumors or thymoma

    Theoretical
  • Unregulated product quality from research-grade sources

    High
  • Contraindicated in pregnancy, lactation, and specific populations

    Moderate
  • Mild injection site reactions

    Low
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.